Cartesian Therapeutics (RNAC) Asset Utilization Ratio (2016 - 2026)

Cartesian Therapeutics (RNAC) has reported Asset Utilization Ratio for 11 consecutive years, with 0.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Asset Utilization Ratio fell 95.59% year-over-year to 0.0; the TTM figure through Mar 2026 stood at 0.0 (down 95.59% YoY), while the FY2025 annual figure was 0.01, down 92.61% from the prior year.
• Asset Utilization Ratio slipped to 0.0 in Q1 2026 per RNAC's latest filing, from 0.01 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.76 in Q2 2022 and bottomed at 0.0 in Q2 2025.
• Historically, Asset Utilization Ratio has averaged 0.27 across 5 years, with a median of 0.13 in 2023.
• Annual changes were most pronounced in 2022 — Asset Utilization Ratio soared 337.53% — and 2025, when it tumbled 99.59%.
• Cartesian Therapeutics' Asset Utilization Ratio stood at 0.64 in 2022, then tumbled by 80.35% to 0.13 in 2023, then tumbled by 32.04% to 0.09 in 2024, then sank by 92.88% to 0.01 in 2025, then slumped by 42.71% to 0.0 in 2026.
• Business Quant data shows RNAC's Asset Utilization Ratio at 0.0 in Q1 2026, 0.01 in Q4 2025, and 0.0 in Q3 2025.